ClinicalTrials.gg
Active, not recruitingNCT04566900Updated Nov 12, 2026

Neurofeedback to Improve Working Memory in Mild Cognitive Impairment

An interventional study of Neurofeedback and Placebo in Mild Cognitive Impairment, sponsored by University of California, San Diego. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Treatment

How we know

Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,423 studies in Cognitive Dysfunction with a site in United States — 330 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Planned enrollment
326th of 1,147
112 · median 59
Started
2021
with 130 others
No phase
716 of 1,423
182 open now
Primary completion
2026-08
later than 83 of 431 live
Registered
796th of 1,423
by date

Among the 1,423 studies in Cognitive Dysfunction with a site in United States, this one is the 326th largest by planned enrollment of the 1,147 interventional ones that give a count, is one of 131 that started in 2021, is one of 716 with no phase, reaches primary completion later than 83 of the 431 other live ones, and was the 796th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

330 of the 1,423 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

325 more — sign in →

All 330 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,423 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

Mild cognitive impairment (MCI) has been identified as an early phase of Alzheimer's disease (AD), a neurodegenerative disorder expected to affect 13.9 million Americans by 2060. AD causes a progressive cognitive decline, including problems related to learning and memory, that adversely affects life quality. Treatment intervention at the MCI stage of the disease could potentially slow down the rate at which people may convert from MCI to AD. Increasing evidence suggests that abnormal activity in frontal regions of the brain is associated with cognitive deficits observed in AD. Furthermore, previous research has shown that neurofeedback (NFB) training targeting these regions can improve memory, making it a potential treatment for AD. NFB is a technique where an individual learns to change his/her brain function in a particular direction, once that function has been made accessible through a visual or auditory metaphor. We are proposing a novel, computer-based brain-training program to enhance frontal gamma oscillatory activity in individuals with MCI. Results from this study will build the scientific foundation necessary for larger clinical trials dedicated to improving treatment options and outcomes for patients with MCI.

Read the detailed description

This is a randomized, double-blind, clinical trial to test the efficacy of gamma-neurofeedback (G-NFB) compared to a placebo (P-NFB) in individuals with MCI. 112 consented participants will be randomized to receive G-NFB (n=56) or placebo-NFB (n=56) during 30-45 minute sessions twice per week for 12 weeks (24 total sessions). Memory and other cognitive domains will be measured using paper and pencil and computerized tests every 4 weeks during the study and at 4 weeks post completion of study.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • neurofeedback
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet criteria for mild cognitive impairment (MCI).
  2. Living independently.
  3. Literate in English.
  4. Competent to participate in the process and provide voluntary informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Frontal temporal dementia
  2. Active alcohol or substance use disorder within the past year.
  3. Brain cancer
  4. Stroke within the last 2 years
  5. Anti-epileptic medication
  6. Prior head injury involving loss of consciousness
  7. Seizure disorder
  8. Use of medications likely to affect cognitive function (cf. donepezil, memantine). We will not exclude for other medications but will examine their effects and include medications as covariates as appropriate (e.g., presence v. absence; anticholinergic load).
  9. The potential benefits of the study do not outweigh the potential risks of the study, as determined by the PI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Active Treatment

    Subjects will be given a choice of videos consisting of still images set to music. Whether the video progresses and music continues to play will depend on the subject's ability to maintain frontal gamma oscillatory activity within a prespecified range. Over successive weeks, the parameters for positive feedback (music and video progression) will become incrementally more difficult.

    Behavioral: Neurofeedback

  • Sham comparator
    Placebo

    Video and music progression will be random and will not depend on brain activity. Any progression will be by random chance alone.

    Other: Placebo

Interventions

  • BehavioralNeurofeedback

    Neurofeedback is a technique where brain functions are made accessible to the subject in the form of a metaphor. For instance, frontal brain activity may be shown as an airplane flying. Once the activity is made accessible, the subject can modulate it in a pre-specified direction. The parameters used to achieve successful feedback are made difficult over time and hence the brain is taught or conditioned to improve performance.

  • OtherPlacebo

    Subjects in this arm will undergo all of the same testing as active treatment. Music and video progression will not depend on brain activity. Instead feedback will be random.

06

What researchers measure

Primary outcomes

  1. Change in Working Memory accuracy

    Change in the computerized test, N-back will be used to measure working memory.

    Time frame: From baseline to 12 weeks of treatment

Secondary outcomes

  1. Durability of Change in Working Memory accuracy

    Change in the computerized test, N-back will be used to measure working memory.

    Time frame: From baseline to 4weeks post end of study

  2. Change in Gamma Band Response

    Change in Gamma oscillations will be measured while the subject performs the n-back task.

    Time frame: From baseline to 12 weeks of treatment

  3. Durability of Gamma Band Response

    Change in Gamma oscillations will be measured while the subject performs the n-back task.

    Time frame: From baseline to 4weeks post end of study

07

Study locations

1 site
08

References and documents

Publications

  • Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-68. doi: 10.1146/annurev-psych-113011-143750. Epub 2012 Sep 27. PubMed 23020641 ↗
  • Dohnel K, Sommer M, Ibach B, Rothmayr C, Meinhardt J, Hajak G. Neural correlates of emotional working memory in patients with mild cognitive impairment. Neuropsychologia. 2008 Jan 15;46(1):37-48. doi: 10.1016/j.neuropsychologia.2007.08.012. Epub 2007 Aug 23. PubMed 17915264 ↗
  • Leuchter AF, Newton TF, Cook IA, Walter DO, Rosenberg-Thompson S, Lachenbruch PA. Changes in brain functional connectivity in Alzheimer-type and multi-infarct dementia. Brain. 1992 Oct;115 ( Pt 5):1543-61. doi: 10.1093/brain/115.5.1543. PubMed 1422803 ↗
  • Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron. 2006 Oct 5;52(1):155-68. doi: 10.1016/j.neuron.2006.09.020. PubMed 17015233 ↗
  • Stam CJ, van Cappellen van Walsum AM, Pijnenburg YA, Berendse HW, de Munck JC, Scheltens P, van Dijk BW. Generalized synchronization of MEG recordings in Alzheimer's Disease: evidence for involvement of the gamma band. J Clin Neurophysiol. 2002 Dec;19(6):562-74. doi: 10.1097/00004691-200212000-00010. PubMed 12488788 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Aug 2026, 67 months.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 67 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2026 → Aug 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2020
First posted
Sep 28, 2020
StartActual
Jan 1, 2021
Primary completionActual
Aug 30, 2026was Jun 2026
CompletionEst.
Dec 31, 2026was Aug 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Aug 30, 2026 (actual)
Nov 12, 2026
Study completion
Aug 31, 2026→Dec 31, 2026
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jun 30, 2026→Aug 30, 2026 (now actual)
    Study completion Aug 31, 2026→Dec 31, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04566900
Responsible party
Fiza Singh (Associate Professor of Psychiatry, University of California, San Diego) — Principal investigator
First posted
Sep 28, 2020
Start date
Jan 1, 2021
Primary completion
Aug 30, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion